Completed PHASE1 INTERVENTIONAL 8-arm NCT02475213

Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer

A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Pembrolizumab and in Combination With MGA012 in Patients With Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer, Urothelial Cancer, and Other Cancers

Sponsor: MacroGenics

Conditions Head and Neck Cancer Melanoma Non Small Cell Lung Cancer Urothelial Carcinoma

Interventions Enoblituzumab Schedule 1 Enoblituzumab Schedule 2 Pembrolizumab retifanlimab

Updated 18 times since 2017 Last updated: Aug 4, 2025 Started: Jul 31, 2015 Primary completion: Aug 18, 2021 Completion: Aug 18, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Head and Neck Cancer and Melanoma and is currently completed. MacroGenics leads this study, which shows 18 recorded versions since 2015 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

18 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Oct 2021 — Jul 2024 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
May 2021 — Oct 2021 [monthly]

Active Not Recruiting PHASE1

▶ Show 13 earlier versions

Jan 2021 — May 2021 [monthly]

Active Not Recruiting PHASE1
Nov 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE1
May 2020 — Nov 2020 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Mar 2020 — May 2020 [monthly]

Recruiting PHASE1
Oct 2019 — Mar 2020 [monthly]

Recruiting PHASE1
Sep 2019 — Oct 2019 [monthly]

Recruiting PHASE1

Status: Active Not Recruiting → Recruiting
Apr 2019 — Sep 2019 [monthly]

Active Not Recruiting PHASE1
Feb 2019 — Apr 2019 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Jun 2018 — Feb 2019 [monthly]

Recruiting PHASE1
Feb 2018 — Jun 2018 [monthly]

Recruiting PHASE1
May 2017 — Feb 2018 [monthly]

Recruiting PHASE1
Feb 2017 — May 2017 [monthly]

Recruiting PHASE1
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE1

First recorded

Jul 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

MacroGenics

Data source: MacroGenics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Boston, United States , Buffalo, United States , Canton, United States , Dallas, United States , Grand Rapids, United States , Greenville, United States , Jacksonville, United States , Las Vegas, United States , Louisville, United States and 10 more locations